Aminophylline for treating asthma and chronic obstructive pulmonary disease

摘要

Aminophylline is a complex of theophylline and ethylenediamine. Its main pharmacological action is relaxation of bronchial smooth muscle. Two meta-analyses examining the efficacy of aminophylline in acute asthma attacks in children and in adults have been reported by the Cochrane Collaboration. In the meta-analysis reporting results from studies in children, it was concluded that aminophylline does not add any benefit to standard care. Yet one study, which has the largest patient population, reports that aminophylline improves lung functions within 6–8 h and reduces the risk of intubation. The meta-analysis examining adult studies revealed that there is no outstanding difference between aminophylline and standard therapy in the management of adult acute asthma. In conclusion, aminophylline may be an alternative to intravenous infusion of β-agonists, heliox or magnesium sulfate administration in children in whom respiratory fatigue begins to develop and intensive-care unit admission and mechanical ventilation seems to be the next treatment in line. However, in adults, it is not recommended for use in the treatment of acute asthma owing to its possible adverse effects.